These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35003091)

  • 1. Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT.
    Luterbacher F; Bernard F; Baleydier F; Ranza E; Jandus P; Blanchard-Rohner G
    Front Immunol; 2021; 12():773853. PubMed ID: 35003091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent Hypogammaglobulinemia after Receiving Rituximab Post-HSCT Is Not Caused by an Intrinsic B Cell Defect.
    Ott de Bruin LM; Pico-Knijnenburg I; van Ostaijen-Ten Dam MM; Weitering TJ; Berghuis D; Bredius RGM; Lankester AC; van der Burg M
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypogammaglobulinemia in Children After Hematopoietic Stem Cell Transplantation and Rituximab Treatment: Relevance of B Cell Subsets.
    Marzollo A; Serena T; Mainardi C; Calore E; Pillon M; Carraro E; Tosato F; Biffi A; Tumino M
    J Pediatr Hematol Oncol; 2023 Jan; 45(1):e145-e149. PubMed ID: 36598967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy.
    Mizuhara K; Fujii N; Meguri Y; Takahashi T; Aoe M; Nakamura M; Seike K; Sando Y; Fujii K; Abe M; Sumii Y; Urata T; Fujiwara Y; Saeki K; Asada N; Ennishi D; Nishimori H; Matsuoka KI; Maeda Y
    Int J Hematol; 2020 Sep; 112(3):422-426. PubMed ID: 32342335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients.
    Labrosse R; Barmettler S; Derfalvi B; Blincoe A; Cros G; Lacombe-Barrios J; Barsalou J; Yang N; Alrumayyan N; Sinclair J; Ong MS; Camargo CA; Walter J; Haddad E
    J Allergy Clin Immunol; 2021 Aug; 148(2):523-532.e8. PubMed ID: 33862010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
    Yamamoto N; Nishimura N; Takeuchi M; Ito T; Yokozaki H; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Nishio H; Matsuo M; Imadome K; Iijima K
    Eur J Pediatr; 2014 Dec; 173(12):1615-8. PubMed ID: 24169729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
    Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
    J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.
    Raberahona M; Wackenheim C; Germi R; Carré M; Bulabois CE; Thiébaut A; Lupo J; Semenova T; Cahn JY; Morand P; Epaulard O
    Transpl Infect Dis; 2016 Dec; 18(6):889-895. PubMed ID: 27696681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.
    Parmentier C; Delbet JD; Decramer S; Boyer O; Hogan J; Ulinski T
    Pediatr Nephrol; 2020 Mar; 35(3):455-462. PubMed ID: 31705306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.
    Levy R; Mahévas M; Galicier L; Boutboul D; Moroch J; Loustau V; Guillaud C; Languille L; Fain O; Bierling P; Khellaf M; Michel M; Oksenhendler E; Godeau B
    Autoimmun Rev; 2014 Oct; 13(10):1055-63. PubMed ID: 25183241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
    Kim BK; Kang HJ; Hong KT; An HY; Choi JY; Lee JS; Park SS; Shin HY
    Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
    Tieu J; Smith RM; Gopaluni S; Kumararatne DS; McClure M; Manson A; Houghton S; Jayne DRW
    Front Immunol; 2021; 12():671503. PubMed ID: 34054846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: Persistent hypogammaglobulinemia and mixed chimerism after HLA class-II disparate-hematopoietic stem cell transplant.
    de Gier M; Pico-Knijnenburg I; van Ostaijen-Ten Dam MM; Berghuis D; Smiers FJ; van Beek AA; Jolink H; Jansen PM; Lankester AC; van der Burg M
    Front Immunol; 2024; 15():1397567. PubMed ID: 39044816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation.
    Delapierre B; Reman O; Dina J; Breuil C; Bellal M; Johnson-Ansah H; Gac AC; Damaj G; Chantepie S
    Curr Res Transl Med; 2019 Nov; 67(4):145-148. PubMed ID: 30871955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary rituximab-associated versus primary immunodeficiencies: The enigmatic border.
    Ottaviano G; Sgrulletti M; Moschese V
    Eur J Immunol; 2022 Oct; 52(10):1572-1580. PubMed ID: 35892275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypogammaglobulinemia in children after allogeneic hematopoietic stem cell transplantation: a cytokine mediated immunoglobulin isotype class switch arrest?
    Sundin M; Remberger M; Lindqvist H; Omazic B; Sundberg B; Uzunel M; Winiarski J
    Pediatr Blood Cancer; 2015 May; 62(5):890-6. PubMed ID: 25623620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab-induced Cytokine Storm in the Absence of Overt Lymphoproliferative Disease.
    Williams M; Khalid T; Hughes S; Bonney D; Wynn R
    J Pediatr Hematol Oncol; 2016 Jan; 38(1):e29-31. PubMed ID: 26583621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia.
    Kridin K; Ahmed AR
    Autoimmun Rev; 2020 Mar; 19(3):102466. PubMed ID: 31917267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.